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Abstract
Recent expert reviews recommend a conservative surgical strategy – debridement and irrigation, antibiotics and implant retention (DAIR) –
for most early post-surgical prosthetic joint infections (PJI). However, differences exist in published series regarding success rates with
DAIR, and the size of most series is small. In this prospective multicenter cohort study of early PJI managed by DAIR, factors associated with
failure of the DAIR were analyzed. Out of 139 early PJI, 117 cases managed with DAIR were studied For 67 patients (57.3%), infection was
cured and the implant was salvaged with deﬁnite antimicrobial therapy. In 35 (29.9%) DAIR failed and removal of the prosthesis was neces-
sary during follow-up. Finally, 15 patients (12.8%) needed chronic suppressive antimicrobial therapy due to suspected or conﬁrmed persis-
tent infection. Infections due to methicillin-resistant S. aureus (72.7% failed; p 0.05) and those treated at one of the hospitals (80.0% failed;
p <0.05) had worse outcomes, but only this last variable was associated with treatment failure following multivariate analysis. Seventy-four
per cent of patients who were successfully treated by DAIR and only 32.7% of the failures were able to walk without help or with one stick
at the last follow-up visit (p <0.05). In conclusion, a substantial proportion of patients with an early PJI may be successfully treated with
DAIR and deﬁnite antimicrobial therapy. In more than half of these, the infection can be cured. Since identiﬁcation of factors associated with
failure of DAIR is not simple, we recommend offering DAIR to most patients with early PJI.
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Introduction
Prosthetic joint infections (PJI) cause great suffering for the
patients and increase hospital stays and costs [1]. The appro-
priateness of implant retention in the management of a PJI is
still a matter of controversy. Success rates for a conservative
strategy consisting in debridement, irrigation and prosthesis
retention followed by antibiotics (DAIR), vary widely in liter-
ature series, from almost 0% to 100% [2]. The main difﬁculty
in interpreting results lies in the different criteria used to
select patients for a DAIR and the classiﬁcation of PJI used.
The only double-blind randomized clinical trial available
regarding DAIR for orthopedic implant related infections
included only 15 cases of PJI [3].
Recent reviews recommend DAIR for most early PJI [4–6],
however important differences appear regarding the success
rates for this strategy (20–100%) [7,8], the limits used to
consider an infection as ‘early’ (2 weeks to 3 months) [9,10]
and the duration of medical therapy (4 weeks to 12 months)
[11–13]. Moreover, the low number of patients studied in
most series provide results with wide conﬁdence intervals.
For some patients, the alternative to DAIR is an instru-
mental arthrodesis or a Girdlestone arthroplasty, which may
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provide limited functional results. Other advantages of DAIR
are that it is a more straightforward procedure with shorter
hospital stays.
Nevertheless, this strategy is generally associated with
more failures than prosthesis removal. Thus, knowledge on
more precise success rates and factors associated with fail-
ure are of paramount importance, especially as the number
of PJI is expected to multiply in the next decades [14]. The
aim of the present study was to analyze a large multicenter
series of early PJI treated with DAIR, according to a com-
mon guide, in order to determine the efﬁcacy of this strategy
and to identify factors associated with treatment failure.
Methods
From January 2004 to December 2006, all patients with PJI
were prospectively evaluated in nine Spanish hospitals
included in the REIPI (Spanish Network for Research in
Infectious Disease) program. Participants agreed on com-
mon deﬁnitions and management of PJI. A standardized case
report form was used to record patient data. Early PJI was
deﬁned as evidence of purulent ﬂuid surrounding the pros-
thesis and/or positive culture from synovial ﬂuid or peri-
prosthetic tissues within the ﬁrst 30 days following
arthroplasty. DAIR was recommended unless the orthope-
dic surgeon decided on removal, for example due to loos-
ening of the implant or excessive soft tissue damage.
Recommended surgical debridement consisted in extensive
cleaning of devitalized tissues, generous saline irrigation and
exchange of the polyethylene component. All patients were
followed during hospitalization, and at scheduled visits as
outpatients, by an infectious diseases specialist with experi-
ence in the management of orthopedic infections. Guide-
lines for antimicrobial therapy included the following
principles:
• Parenteral antimicrobial therapy starting as soon as cul-
tures were obtained. Oral antibiotics could substitute
intravenous antibiotics at the investigator’s judgment.
• Antimicrobial therapy should be maintained for 6–
12 weeks. Longer therapies were accepted based on the
investigator’s clinical judgment. This included the use of
suppressive antimicrobial therapy [15,16].
• For staphylococcal infections rifampicin was added if the
strain was susceptible.
• For MRSA strains, vancomycin was considered the initial
therapy of choice. Oral alternatives included trimetho-
prim-sulfamethoxazole, linezolid, fusidic acid and clinda-
mycin if the strain was susceptible.
• For Pseudomonas aeruginosa infections, combined therapy
was recommended during the ﬁrst 3 weeks.
• For the rest of pathogens, monotherapy was considered
sufﬁcient. Fluoroquinolones were the preferred agents
for Gram-negative microorganisms.
At the last follow-up visit, patients were classiﬁed into three
categories: (A) After debridement the patient was given anti-
microbial therapy for a deﬁnite time. During the follow-up
there was no evidence of relapse. (B) After debridement the
patient was given suppressive antimicrobial therapy due to a
presumed or conﬁrmed persistent infection, (for example,
CRP did not return to normal value). (C) After debridement
the patient was given antimicrobial therapy for a deﬁnite per-
iod of time. During follow-up, removal of the implant was
necessary due to persistent or relapsing infection. For the
purposes of the analysis, categories B and C were consid-
ered ‘failures’. Functional status was recorded at the last fol-
low-up visit by asking the patients if they were able to walk
without help, with one stick, with two sticks or if they were
not able to walk at all.
Frequencies and conﬁdence intervals for categorical vari-
ables, and mean or median and interquartile range (IQR) for
continuous variables were used if their distribution departed
from normality. The Chi squared or Mantel-Haenszel test
and Mann Whitney U tests were used for the univariate anal-
ysis. A multivariate logistic regression model was developed
to analyze factors associated with failure of DAIR. The maxi-
mal model included all variables associated with a p <0.1. A
backward strategy, using the value p <0.05 to eliminate vari-
ables from the model, was implemented. The likelihood ratio
test was used for model comparison and goodness of ﬁt
assessment.
Results
One hundred and thirty-nine patients were included in the
study. Table 1 summarizes the demographic features.
Patients were hospitalized for a mean of 58 days. S. aureus
(39.6%) was the most common pathogen (Table 2). Cases
were followed for a mean of 749 (6–1857) days. Thirty-nine
patients (28%) died during follow-up, but only ﬁve deaths
were considered related to the infection. Live patients were
followed for a mean of 879 days. The study population
included 117 cases treated by DAIR (Fig. 1).
Sixty-seven cases (57.3%; 95% CI: 48.3–66.2) were classi-
ﬁed as group A, 35 (29.9%; 95% CI: 21.6–38.2) as group C,
and 15 (12.8%; 95% CI: 6.8–18.9) as group B. Thus, in 82
cases (70.1%; 95% CI: 61.8–78.4) treated with DAIR it was
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possible to manage the infection without prosthesis removal.
If the entire population is considered (the clinical scenario
before the decision to salvage the implant) and excluding the
ﬁve early deaths, in 50% (CI 95%: 41.5–58.5) of cases the
infection could be cured and the implant salvaged by DAIR.
Percentages of salvaged implants with DAIR reached 61.2%
(CI 95%: 52.9–69.4), including the patients that were rescued
by suppressive antimicrobial therapy.
Possible factors associated with failure of DAIR (group B
or C vs. Group A) were examined (Table 3). Age, sex,
presence of co-morbidity and location of the implant were
not associated with failure. The success rates for infections
caused by organisms considered to be less virulent (CNS,
Corynebacterium spp., alpha-hemolytic streptococci) was simi-
lar to that observed for infections caused by bacteria
traditionally considered to be more virulent such as entero-
bacteriaceae, S. aureus or P. aeruginosa. Infections caused by
S. aureus presented similar outcomes with DAIR than infec-
tions produced by other microorganisms (58% vs. 57%).
TABLE 1. Demographic features of the 139 early prosthetic
joint infections
Total (percentage)
Age (median) 76.8
Female 92 (66.2)
Prosthesis location
Total hip replacement 69 (49.6)
Hip hemiarthroplasty 15 (10.8)
Knee 53 (38.1)
Shoulder 2 (1.4)
Type of prosthesisa
Primary 92 (62.2)
Secondary 37 (26.6)
Tertiary 9 (6.5)
Co-morbidity
None 42 (30.2)
Diabetes 35 (25.2)
Cancer 12 (8.6)
Autoimmune diseases 12 (8.6)
aData from 138 patients.
TABLE 2. Microbiology of 139 early PJI
Aerobic Gram-positive
CNS 34
MSSA 38
MRSA 17
Enteroccocci 17
Streptococci 5
Aerobic Gram-negative
E. coli 15
Other enterobacteria 30
Pseudomonas aeruginosa 17
Anaerobes 11
Monomicrobial 87
Polymicrobial 45
Culture negative 7
CNS, coagulase-negative staphylococci; MSSA, methicillin-susceptible S. aureus;
MRSA, methicillin-resistant S. aureus.
139 EPJI
118 EPJI
(prosthesis retained)
2 insufficient data
2 early death
17 prosthesis removed
67 group A 35 group C15 group B
1 early death
2 early death
117 EPJI
(study population)
FIG. 1. Description of outcomes of early PJI treated with conserva-
tive strategy (see text for deﬁnition of groups A, B and C).
TABLE 3. Factors associated with failure of the conservative
strategy
Variable
Success
(group A)
n = 67
Failure (grou
ps B and C)
n = 50 p
Sex
Female (78) 44 (56.4%) 34 (46.3%) 0.79
Age, years (median) 76.8 79.9 0.13a
Co-morbidity
Yes (82) 45 (54.9%) 37 (45.1%) 0.42
Location of prosthesis
Total hip (57) 27 (47.4%) 30 (52.6%) 0.13
Hip Hemiarthroplasty (13) 10 (76.9%) 3 (23.1%)
Total knee (46) 29 (63%) 17 (37%)
Shoulder (1) 1 (100%)
Prosthesis (data from 116 cases)
Primary (76) 46 (60.5%) 30 (39.5%) 0.29
Secondary (31) 18 (58.1%) 13 (41.9%)
Tertiary (9) 3 (33.3%) 6 (66.6%)
Etiology
Low virulenceb (29) 14 (48.3%) 15 (51.7%) 0.25
S. aureus (both) (43) 25 (58.1%) 18 (41.9%) 0.88
MRSA (11) 3 (27.3%) 8 (72.7%) 0.05
Use of rifampicinc (65)
Yes (57) 35 (61.4%) 22 (38.6%) 0.36
Hospital
A (17) 8 (47.1%) 9 (52.9) 0.009d
B (42) 29 (69.0%) 13 (31.0%)
C (20) 4 (20.0%) 16 (80.0%)
D (9) 7 (77.8%) 2 (22.2%)
E (3) 1 (33.3%) 2 (66.6%)
F (8) 6 (75.0%) 2 (25.0%)
G (11) 9 (81.8%) 2 (18.2%)
H (5) 1 (20.0%) 4 (80.0%)
I (2) 2 (100%) 0 (0%)
Mean time from implant to
debridement in days (median)
23.5 (21) 30.6 (23) 0.19a
Mean from symptoms to
debridement, mean in
days (median)
10.2 (7) 15.7 (10) 0.08a
Mean time on antibiotic
therapy in days (median)
80.6 (60) 84.3 (85) 0.58a
aMann-Whitney U test.
bLow virulence: patients with isolation of enterococci, CNS, Corynebacterium
spp, or alfa-haemolytic streptococci and absence of other bacteria considered
virulent (S. aureus, Gram-negative bacilli, anaerobes).
cCalculated only among patients with staphylococcal infections. Eight out of 11
MRSA cases received rifampicin: three were classiﬁed as success. All three
MRSA patients not treated with rifampicin were failures.
dHospitals with at least nine cases which could be evaluated were compared.
Percentage of success was signiﬁcantly lower for hospital C.
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Nevertheless, only three of 11 MRSA infections (27.3%)
were cured by DAIR (p 0.05).
One of the hospitals presented lower success rates than
the others. Only four out of 20 early PJI were cured and sal-
vaged at hospital ‘C’. This difference was statistically signiﬁ-
cant when comparing success rates at hospital C with
success rates at other hospitals that contributed at least nine
cases to the series. Time from the onset of ﬁrst symptoms
until debridement was longer for failures than for patients
successfully treated by DAIR (mean 15.7 vs.10.2 days respec-
tively; p 0.08). The same trend was observed when we con-
sidered time between prosthesis implantation and the
debridement of infected tissue (Table 3). When analysing
duration of therapy in patients with failure and success we
excluded cases classiﬁed as group B, since these patients
received suppressive antimicrobial therapy. No statistically
signiﬁcant differences were found among patients in groups
A and C, who received a mean of 80.6 days (median
60 days) and a mean of 84.3 days (median 85) of therapy
respectively.
The only variable associated with failure by multivariate
analysis was being attended at hospital C. We searched for
possible factors associated with failure or success, excluding
group B patients from the analysis. No others variables
appeared to be associated with failure in the univariate analy-
sis (data not shown).
Finally, functional status could be analyzed at the last fol-
low-up visit for 115 patients. Forty-nine of 66 (74.2%) suc-
cessfully treated patients but only 16 of 49 failures (32.7%)
were able to walk without help or with the aid of one stick,
and this difference was statistically signiﬁcant (p <0.01).
Discussion
In this multicenter study we have shown that a considerable
percentage of patients with an early PJI can be successfully
treated with DAIR. In more than half the cases, in fact, the
infection can be cured (as observed after 2-years of follow-
up) and some patients in which there is suspected or con-
ﬁrmed persistence or relapse of infection can be managed
with suppressive antimicrobial therapy. Functional results of
this strategy were good since approximately three quarters
of the successfully treated patients were able to walk with
little or no help.
The main difﬁculty in interpreting literature results on the
subject of PJI is the variability of deﬁnitions and criteria used
to classify PJI in addition to a large variability in the medical
management of cases. In our opinion, the approach given by
Tsukayama et al. provides a simple and practical classiﬁcation
with clinical and therapeutic implications [11]. In that series,
early PJI were managed by DAIR followed by medical therapy
for a deﬁnite period of time. With this strategy, success
rates reached 71%. On the other hand, chronic infections
need to be managed with removal of the implant [7]. Hema-
togenous PJI are a type of PJI infections that appear suddenly,
months or years after surgey. They are usually published
together with early PJI, because of their acute nature, but
following Tsukayama’s classiﬁcation, we decided to study
them separately (Dr. Rodriguez, in press).
As we previously mentioned, even restricting the analy-
sis to reports of early PJI, a considerable variation in suc-
cess rates with DAIR is observed. Most series do not
provide data regarding the number of patients in whom
DAIR was excluded [3,8,10,17]. Perhaps, more successful
series selected their candidates for DAIR more strictly
[8,12]. Such policies would have the disadvantage of not
offering DAIR to patients who could salvage their implants.
Other explanations for the large variability in the results
of DAIR are the use of different medical therapies at dif-
ferent centers, as well as diverse debridement techniques,
and different lengths of follow-up. The appropriateness of
more than one debridement procedure for some patients
is an interesting and unresolved issue. For some authors
the need for a second debridement represents a failure
while others report that half the patients needed two or
more debridement procedures, considering that a second
debridement is not a failure, as for post-surgical septic
arthritis [12,18]. In fact, in at least one series this variable
is presented as a factor contributing to their excellent out-
comes [8].
When to stop antimicrobial therapy in patients with DAIR
and a favorable clinical course remains an open question.
While most authors use antibiotic therapy for several weeks
after debridement and irrigation of the joint in early PJI
[7,10,11,13,19–21], others use prolonged or, even, suppres-
sive antimicrobial therapy after debridement, regardless of
the type of PJI treated [12,17,22]. Nevertheless, in some
studies, favorable outcomes have been reported with only
4 weeks of therapy [11,13]. In our series, duration of ther-
apy (approximately 2.5 months) was similar for cured (group
A) patients and failures (group C). Thus, it seems that, at
least for a substantial proportion of patients, it is not neces-
sary to give more than 3 months of antibiotic therapy after
debridement. Nevertheless, we cannot exclude that longer
duration of therapy could improve overall results. Data from
one study suggest that once a chronic infection is estab-
lished, antibiotics only delay the failure [22]. Nevertheless, it
supports the use of chronic suppressive antibiotics for
selected patients.
CMI Cobo et al. Early prosthetic joint infections 1635
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1632–1637
Several studies have stressed the duration of the symp-
toms before debridement as a crucial prognostic factor for
success of DAIR [23–25], but unfortunately these studies do
not provide the time from prosthesis implantation to onset
of symptoms. In our opinion, the variable ‘short duration
from symptoms to debridement’ could simply be a surrogate
marker for acute (early or hematogenous) PJI. In our series,
no time-dependent variables were associated with success
but a trend towards a shorter time between appearance of
symptoms and debridement was observed among successfully
treated patients.
Some investigators found that DAIR in acute PJI due to
S. aureus were associated with a worse prognosis [26,27],
suggesting that once this pathogen is identiﬁed a two-stage
exchange procedure should be performed. However, the
only double-blind published clinical trial obtained 100% suc-
cess treating orthopaedic associated infections (including PJI)
caused by S. aureus with rifampicin combinations [3]. More-
over, recent series of early (or ‘acute’) PJI have reported
favourable results in spite of a high proportion of cases due
to S. aureus [10,20]. In our series, cure rates were similar
for S. aureus infections and those caused by other pathogens.
However, early PJI caused by MRSA were associated with
higher failure rates. Similar results have been previously
reported [28–30].
Failures were signiﬁcantly more frequent in one hospital.
The difference was due to a high percentage of cases classi-
ﬁed as group B. However the percentage of patients that
needed excision or exchange of the arthroplasty was similar
to the other centers. With the available information it was
not possible to determine whether the differences were due
to differences in the population (patients in hospital C were
4.5 years older; p 0.079), or to a local investigator’s ten-
dency to suspect persistent infection.
Some strengths of our series include the number of cases
studied (the largest published to our knowledge regarding
early PJI), its prospective nature, a precise case deﬁnition
and common guidelines for the management of cases. We
also provide data regarding early PJI in which DAIR was not
selected (pre-determined), which reﬂects everyday practice
better, including the clinical scenario in which the decision to
save the implant has not been taken yet. Among the limita-
tions of our study, the multicenter nature of our series
implies some heterogeneity due to differing criteria for use
of suppressive antimicrobial therapy and variability in surgical
techniques. A longer duration of follow-up would also have
been desirable. Moreover, our database does not allow us to
assess the impact of inadequate empirical therapy on failure.
Since no clear factors allow prediction of failure, we con-
clude that, in the absence of any contraindication, such as
prosthesis loosening, most patients with early PJI infection
should be offered DAIR. In spite of a moderate success rate
with this strategy most patients may have the opportunity to
salvage and even cure their implant- associated infection by
means of a simpler and less costly procedure. Either a more
aggressive surgical therapy (prosthesis exchange or arthrode-
sis) or suppressive antimicrobial therapy can be offered if
DAIR fails.
Other treatment aspects such as appropriateness of DAIR
for PJI that appear in the second and third month after sur-
gery, the convenience of subsequent debridement, the
importance of surgical team skills, the optimal duration of
therapy, and the role of rifampicin in combination with other
agents different from ﬂuoroquinolones, need to be clariﬁed
by new series and clinical trials.
Acknowledgements
We thank Alfonso Muriel for his assistance with statistical
analysis and Francesca Norman for her review of the English
version. Drs. D. Rodriguez, G. Euba and L. San Miguel
received a research grant from Ministerio de Sanidad y Con-
sumo, Instituto de Salud Carlos III, Spanish Network for the
Research in Infectious Diseases (REIPI RD 06/0008).
Transparency Declaration
The authors have no relevant ﬁnancial interests related to
this article.
References
1. Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge
for infectious disease specialists. Clin Infect Dis 2003; 36: 1157–1161.
2. Silva M, Tharani R, Schmalzried TP. Results of direct exchange or
debridement of the infected total knee arthroplasty. Clin Orthop Relat
Res 2002; 404: 125–131.
3. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of
rifampin for treatment of orthopaedic implant-related staphylococcal
infections: a randomized controlled trial. Foreign-Body Infection (FBI)
Study Group. JAMA 1998; 279: 1537–1541.
4. Barberan J. Management of infections of osteoarticular prosthesis.
Clin Microbiol Infect 2006; 12 (suppl 3): 93–101.
5. Zimmerli W, Ochsner PE. Management of infection associated with
prosthetic joints. Infection 2003; 31: 99–108.
6. Ariza J, Euba G, Murillo O. [Orthopaedic device-related infections].
Enferm Infecc Microbiol Clin 2008; 26: 380–390.
7. Crockarell JR, Hanssen AD, Osmon DR, Morrey BF. Treatment of
infection with debridement and retention of the components follow-
ing hip arthroplasty. J Bone Joint Surg Am 1998; 80: 1306–1313.
1636 Clinical Microbiology and Infection, Volume 17 Number 11, November 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1632–1637
8. Mont MA, Waldman B, Banerjee C, Pacheco IH, Hungerford DS.
Multiple irrigation, debridement, and retention of components in
infected total knee arthroplasty. J Arthroplasty 1997; 12: 426–433.
9. Teeny SM, Dorr L, Murata G, Conaty P. Treatment of infected total
knee arthroplasty. Irrigation and debridement versus two-stage reim-
plantation. J Arthroplasty 1990; 5: 35–39.
10. Soriano A, Garcia S, Bori G et al. Treatment of acute post-surgical
infection of joint arthroplasty. Clin Microbiol Infect 2006; 12: 930–933.
11. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip
arthroplasty. A study of the treatment of one hundred and six infec-
tions. J Bone Joint Surg Am 1996; 78: 512–523.
12. Aboltins CA, Page MA, Buising KL et al. Treatment of staphylococcal
prosthetic joint infections with debridement, prosthesis retention and
oral rifampin and fusidic acid. Clin Microbiol Infect 2007; 13: 586–591.
13. Segawa H, Tsukayama DT, Kyle RF, Becker DA, Gustilo RB. Infection
after total knee arthroplasty. A retrospective study of the treatment
of eighty-one infections. J Bone Joint Surg Am 1999; 81: 1434–1445.
14. Kurtz SM, Ong KL, Schmier J et al. Future clinical and economic
impact of revision total hip and knee arthroplasty. J Bone Joint Surg
Am 2007; 89 (suppl 3): 144–151.
15. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic
therapy for infected orthopaedic prostheses. Clin Infect Dis 1998; 27:
711–713.
16. Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of
infection in total joint arthroplasty. Clin Orthop Relat Res 2003; 414:
55–60.
17. Marculescu CE, Berbari EF, Hanssen AD et al. Outcome of prosthetic
joint infections treated with debridement and retention of compo-
nents. Clin Infect Dis 2006; 42: 471–478.
18. Judd D, Bottoni C, Kim D, Burke M, Hooker S. Infections following
arthroscopic anterior cruciate ligament reconstruction. Arthroscopy
2006; 22: 375–384.
19. Berdal JE, Skramm I, Mowinckel P, Gulbrandsen P, Bjornholt JV. Use
of rifampin and ciproﬂoxacin combination therapy after surgical
debridement in the treatment of early manifestation prosthetic joint
infections. Clin Microbiol Infect 2005; 11: 843–845.
20. Barberan J, Aguilar L, Carroquino G et al. Conservative treatment of
staphylococcal prosthetic joint infections in elderly patients. Am J
Med 2006; 119: 993. e7–e10.
21. Deirmengian C, Greenbaum J, Stern J et al. Open debridement of
acute gram-positive infections after total knee arthroplasty. Clin Ort-
hop Relat Res 2003; 416: 129–134.
22. Byren I, Bejon P, Atkins BL et al. One hundred and twelve infected
arthroplasties treated with ‘DAIR’ (debridement, antibiotics and
implant retention): antibiotic duration and outcome. J Antimicrob Che-
mother 2009; 63: 1264–1271.
23. Brandt CM, Sistrunk WW, Duffy MC et al. Staphylococcus aureus
prosthetic joint infection treated with debridement and prosthesis
retention. Clin Infect Dis 1997; 24: 914–919.
24. Tattevin P, Cremieux AC, Pottier P, Huten D, Carbon C. Prosthetic
joint infection: when can prosthesis salvage be considered? Clin Infect
Dis 1999; 29: 292–295.
25. Burger RR, Basch T, Hopson CN. Implant salvage in infected total
knee arthroplasty. Clin Orthop Relat Res 1991; 273: 105–112.
26. Deirmengian C, Greenbaum J, Lotke PA, Booth RE Jr, Lonner JH.
Limited success with open debridement and retention of components
in the treatment of acute Staphylococcus aureus infections after total
knee arthroplasty. J Arthroplasty 2003; 18 (suppl 1): 22–26.
27. Schoifet SD, Morrey BF. Treatment of infection after total knee
arthroplasty by debridement with retention of the components.
J Bone Joint Surg Am 1990; 72: 1383–1390.
28. Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure
of methicillin-resistant Staphylococcus aureus prosthetic joint infec-
tions. Clin Orthop Relat Res 2007; 461: 48–53.
29. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee
infections caused by resistant bacteria. Clin Orthop Relat Res 2002;
404: 116–124.
30. Bradbury T, Fehring TK, Taunton M et al. The fate of acute methicil-
lin-resistant Staphylococcus aureus periprosthetic knee infections
treated by open debridement and retention of components. J Arthro-
plasty 2009; 24 (6 suppl): 101–104.
CMI Cobo et al. Early prosthetic joint infections 1637
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1632–1637
